An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial.

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 44; pp. 227 - 247
Autores principales: Xu, Cheng, Qu, Song, Liu, Zhigang, Yang, Kunyu, Huang, Ying, Guo, Ling, Luo, Dong-Hua, Tang, Ling-Long, Cai, Qingqing, Xia, Yi, Zhou, Guan-Qun, Zhang, Yuan, Su, Fang, Wang, Zhiqiang, Hong, Xiaohua, Li, Jibin, Li-Zhi, Liu, Tian, Li, Li, Haojiang, Ma, Jun
Formato: Journal Article
Publicado: American Society of Clinical Oncology 2026 Supplement 19
Acceso en línea:Ver este registro en EBSCOhost